文献速递妇科

新型多卡霉素HER2靶向抗体药物偶联物SYD985在HER2/Neu表达上皮性卵巢癌中显示有前景的抗肿瘤活性

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
PubMed 文献 · Gynecol Oncol · 2017-05-01

本研究比较新型HER2靶向抗体药物偶联物SYD985与曲妥珠单抗美坦新(T-DM1)在HER2/Neu表达不同的上皮性卵巢癌模型中的抗肿瘤活性。体外实验使用十株原代上皮性卵巢癌细胞系进行抗体依赖细胞介导的细胞毒作用、增殖、活力和旁观者杀伤实验,并在卵巢癌异种移植瘤中研究体内活性。结果表明SYD985较T-DM1细胞毒性更强,且能有效旁观者杀伤HER2/Neu 0/1+肿瘤细胞,体内对HER2/Neu 3+上皮性卵巢癌异种移植瘤活性显著更高。

要点

  • SYD985与T-DM1在外周血淋巴细胞存在时诱导相似ADCC。
  • 无外周血淋巴细胞时SYD985较T-DM1细胞毒性强3至42倍(p<0.0001)。
  • SYD985可旁观者杀伤HER2/Neu 0/1+肿瘤细胞,T-DM1无此作用。

核心结论

  • SYD985是对强(3+)及中低(即2+和1+)HER2/Neu表达上皮性卵巢癌有显著活性的新型抗体药物偶联物。
  • 在对比实验中SYD985比T-DM1更强效,且不同于T-DM1,对中低或不均一HER2/Neu表达的上皮性卵巢癌有活性。

研究设计与样本

  • 研究使用十株原代上皮性卵巢癌细胞系,HER2/Neu表达为0/1+、2+和3+,进行抗体依赖细胞介导的细胞毒作用、增殖、活力和旁观者杀伤实验。
  • 在卵巢癌异种移植瘤中研究SYD985和T-DM1的体内活性。

主要发现

  • 在外周血淋巴细胞存在时,SYD985和T-DM1对HER2/Neu表达不同的上皮性卵巢癌细胞系诱导相似的ADCC。
  • 无外周血淋巴细胞时,SYD985较T-DM1细胞毒性强3至42倍(p<0.0001)。
  • 与T-DM1不同,SYD985与HER2/Neu 3+上皮性卵巢癌细胞混合时,对HER2/Neu 0/1+肿瘤细胞诱导有效的旁观者杀伤。
  • 体内研究证实SYD985对HER2/Neu 3+上皮性卵巢癌异种移植瘤的活性显著高于T-DM1。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. <10% of EOC demonstrate HER2/neu 3+ receptor over-expression. However, moderate to low (i.e., 2+ and 1+) HER2/neu expression is reported in up to 50% of EOC. The objective of this study was to compare the anti-tumor activity of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC), to trastuzumab emtansine (T-DM1) in EOC models with differential HER2/neu expression. METHODS: The cytotoxicity of SYD985 and T-DM1 was evaluated using ten primary EOC cell lines with 0/1+, 2+, and 3+ HER2/neu expression in antibody-dependent cellular cytotoxicity (ADCC), proliferation, viability and bystander killing experiments. Finally, the in vivo activity of SYD985 and T-DM1 was also studied in ovarian cancer xenografts. RESULTS: SYD985 and T-DM1 induced similar ADCC in the presence of peripheral blood lymphocytes (PBL) against EOC cell lines with differential HER2/neu expression. In contrast, SYD985 was 3 to 42 fold more cytotoxic in the absence of PBL when compared to T-DM1 (p<0.0001). Unlike T-DM1, SYD985 induced efficient bystander killing of HER2/neu 0/1+ tumor cells when admixed with HER2/neu 3+ EOC cells. In vivo studies confirmed that SYD985 is significantly more active than T-DM1 against HER2/neu 3+ EOC xenografts. CONCLUSIONS: SYD985 is a novel ADC with remarkable activity against EOC with strong (3+) as well as moderate to low (i.e., 2+ and 1+) HER2/neu expression. SYD985 is more potent than T-DM1 in comparative experiments and unlike T-DM1, it is active against EOC demonstrating moderate/low or heterogeneous HER2/neu expression.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Menderes G, Bonazzoli E, Bellone S, et al. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecol Oncol. 2017. PMID: 28473206. doi:10.1016/j.ygyno.2017.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。